Navigation Links
DelMar Pharmaceuticals, Inc. Provides Corporate Update for the Quarter Ended March 31, 2013
Date:5/16/2013

e time and receive event updates.

On behalf of the entire DelMar Pharma team, I thank you for your continued support of our mission to develop and commercialize proven therapies for patients who have failed currently available therapy.  As always, our goal remains to serve to patients who have unmet clinical needs and to build value for our shareholders in the timeliest manner possible.

With warm personal regards,
Jeffrey Bacha, BSc , MBA
President & CEO, DelMar Pharmaceuticals , Inc.

About DelMar Pharma

Del Mar Pharmaceuticals was founded in 2010 to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. The Company's lead asset, VAL-083, is currently undergoing clinical trials in the United States as a potential treatment for refractory glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.  VAL-083 benefits from extensive clinical research sponsored by the US National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia (CML) and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's abi
'/>"/>

SOURCE DelMar Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. DelMar Pharmaceuticals to Present Interim Clinical Data on VAL-083 in Refractory Glioblastoma at Society for Neuro-Oncology (SNO) Annual Meeting
2. DelMar Pharmaceuticals Announces $1.0 Million Third Closing in Private Placement
3. DelMar Pharmaceuticals Announces $1.6 Million Closing in Private Placement
4. DelMar Pharmaceuticals Announces Appointment of John K. Bell to Board of Directors
5. DelMar Pharmaceuticals Announces Completion Of $10.5 Million Oversubscribed Offering And Appointment Of Investor Relations Consultant
6. DelMar Pharmaceuticals to Present at the 25th Annual ROTH Capital Partners Growth Stock Conference
7. DelMar Pharma Named to Rocket Builders 2013"Ready to Rocket" List
8. DelMar Pharmaceuticals to Present Clinical Data from VAL-083 Brain Cancer Trial at the American Association of Cancer Research Annual Meeting
9. DelMar Pharma Presents Encouraging Data From Ongoing Phase I/II GBM Clinical Trial With VAL-083
10. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
11. Provectus Pharmaceuticals, Inc.s Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015  EP Global Communications, Inc. (Public ... recently contacted the Company about discussing EPGL,s electronic ... as Monday, August 3, 2015.  Novartis CEO ... that the coming electronic contact lens market could ... the next several years.  Novartis partnered with Google ...
(Date:7/30/2015)... PLAINFIELD, N.J., July 30, 2015 PTC Therapeutics, ... update and reported financial results for the second quarter ... progressing on many fronts across the organization.  We are ... Duchenne muscular dystrophy clinical trial ever conducted with topline ... Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics, Inc. "Translarna ...
(Date:7/30/2015)... 2015  Growth of the U.S. nonprescription market is ... prescription users to the OTC market. Due to an ... Rx-to-OTC switch activity over the next five years with ... new brands entering the market into existing categories. ... years (even those with low to moderate likelihood), the ...
Breaking Medicine Technology:PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 3
... builds on company,s suite of tests to evaluate ... a leading clinical-diagnostics and biomedical-research laboratory specializing in ... diagnostic assay designed to help physicians better understand ... The company will introduce the Pneumococcal Antibody ...
... March 12 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") ... it has started patient enrolment in a Phase ... in combination with paclitaxel and carboplatin in patients ... or EGFR-activated tumours. The Principal Investigator is Dr. ...
Cached Medicine Technology:IBT Laboratories to Launch New Pneumococcal Antibody Avidity Test at AAAAI Meeting, Booth 729 2Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours 2
(Date:7/31/2015)... , ... July 31, 2015 , ... In the most ... U.S. District Court in the Northern District of Illinois, Androgel testosterone attorneys report that ... 20, a docket entry was made recording the minutes of the status conference, which ...
(Date:7/31/2015)... ... July 31, 2015 , ... Intellitec Solutions announced today ... of Microsoft Dynamics GP for a senior living facility in Maine. Having achieved ... living communities in 16 states. This further expansion was again a factor of ...
(Date:7/30/2015)... ... ... When responsible for the care of an aging loved one, summer vacations ... What happens if mom falls? Who will remind Dad to take his medications? What ... not taking time away from caregiving responsibilities can lead to bigger problems – caregiver ...
(Date:7/30/2015)... ... 2015 , ... On July 22nd the Bradenton Herald reported the ... for controlling the heroin outbreak. Ultimately the committee expressed lack of funding, and the ... heroin crisis in North Florida. The task force has proposed to instate counselors to ...
(Date:7/30/2015)... ... July 30, 2015 , ... The ... BioPharma, Inc. are pleased to announce that data standards for clinical research in ... on the CDISC website . These three Therapeutic Area (TA) standards were ...
Breaking Medicine News(10 mins):Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 2Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 3Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 4Health News:Intellitec Solutions Expands Long term Care ERP Offerings to Maine 2Health News:Aging Life Care Association™ Experts Offer Tips for Caregivers in Need of Vacation Time 2Health News:Aging Life Care Association™ Experts Offer Tips for Caregivers in Need of Vacation Time 3Health News:Manatee County’s Opioid Task Force Calls for More Funding and Face to Face Counseling After Overdose 2Health News:Manatee County’s Opioid Task Force Calls for More Funding and Face to Face Counseling After Overdose 3Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 2Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 3Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 4Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 5
... planned spinoff later this summer , , SAN DIEGO, ... public following the planned spinoff of Cardinal Health,s clinical and ... the occasion by providing opportunities for its global employees to ... "This is an exciting day for our company and employees ...
... (Nasdaq: BMRN ) today announced that Jean-Jacques Bienaime, Chief ... on Thursday, July 30, at 5:00 p.m. ET (23:00 CET) to ... U.S. / Canada Dial-in Number: 866.272.9941, ... 45596036, Replay Dial-in Number: 888.286.8010, ...
... Women are more vulnerable during certain stages of ... News) -- Fluctuating hormone levels may explain trends ... diseases such as Parkinson,s, schizophrenia, Alzheimer,s, Tourette,s and ... level changes occur at various stages of women,s ...
... amoxicillin in kids, , WEDNESDAY, July 1 (HealthDay News) ... infections in young children increases the risk of recurrent ... the Netherlands who called for more prudent use of ... 63 percent of children given the antibiotic amoxicillin experienced ...
... safety in those who think the same way, research contends ... you believe, new research suggests that you,re likely to surround ... be friends or talking heads on television. , "Never having ... way of protecting your beliefs. It,s a little bit primitive, ...
... WOODLANDS, Texas, July 1 eCardio Diagnostics ... arrhythmia monitoring services, today announced that it has received a ... round of institutional funding since the company was founded in ... marks a milestone in the growth of eCardio," noted Larry ...
Cached Medicine News:Health News:CareFusion Launches New Brand, Establishing Itself as an Industry Leader in Helping Hospitals Improve Patient Care and Safety 2Health News:CareFusion Launches New Brand, Establishing Itself as an Industry Leader in Helping Hospitals Improve Patient Care and Safety 3Health News:BioMarin to Host Second Quarter 2009 Financial Results Conference Call and Webcast on Thursday, July 30 at 5:00 p.m. ET (23:00 CET) 2Health News:Hormones May Affect Neurological Disease Risk 2Health News:Antibiotics May Boost Risk for Recurrent Ear Infection 2Health News:Your Surroundings Mirror Your Beliefs 2Health News:Your Surroundings Mirror Your Beliefs 3Health News:eCardio Receives Significant Investment in Private Funding from Sequoia Capital 2
... Microalbumin Strips provide albumin, creatinine and albumin-to-creatinine ... Microalbumin product is useful to test for ... in order to detect early kidney disease. ... the urinary albumin excretion rate, is an ...
... to near-patient urinalysis. The Chemstrip ... affordable, reliable alternative to visual ... fundamental, easy-to-use features, the Chemstrip ... office lab, clinic, and hospital ...
... UA is the first hand-held urine ... valuable lab bench space. Automation of ... in results between operators and transcription ... run, corrects for ambient temperature and ...
... first outside-the-balloon, dual-wire dilatation catheter. The ... innovative new approach to dilatation. Its unique, ... wires to create expansion planes at low ... ,The FX miniRAIL RX PTCA Catheter is ...
Medicine Products: